Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabPier Francesco Ferrucci, Chiara Martinoli, Paola Savoia et al.|Annals of Oncology|2016Cited by 398
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access ProgramPaolo A. Ascierto, Michele Maio, Ester Simeone et al.|Cancer Investigation|2014Cited by 105
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabPier Francesco Ferrucci, Chiara Martinoli, Paolo A. Ascierto et al.|Annals of Oncology|2017Cited by 50
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP).Paolo A. Ascierto, Michele Maio, Ester Simeone et al.|Journal of Clinical Oncology|2013Cited by 11